Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321106 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
A Phase 1 study of Colorectal Cancer and Colon Cancer, sponsored by Cartography Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 4
- Study locations
NCT07321106 is a Phase 1 study of Colorectal Cancer and Colon Cancer that is actively recruiting participants, run by Cartography Biosciences. The registered enrollment target is 80 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT07321106, a Phase 1 study of Colorectal Cancer and Colon Cancer, is actively recruiting participants, sponsored by Cartography Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer
Conditions Studied
Interventions
- BIOLOGICAL CBI-1214
Study Locations (4)
California
- Valkyrie Clinical Trials - Los Angeles
Michigan
- START Midwest - Grand Rapids
Texas
- NEXT Oncology - San Antonio
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2029-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07321106
The ClinicalTrials.gov registry entry for NCT07321106 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Cartography Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which CBI-1214 is the first listed.
NCT07321106 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT07321106 about?
NCT07321106 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer". This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer
What is the current status of trial NCT07321106?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2026-01-15. Estimated completion is 2029-10.
What conditions does trial NCT07321106 study?
This clinical trial studies the following conditions: Colorectal Cancer, Colon Cancer, Colorectal Cancer (CRC), CRC, Advanced Colorectal Cancer.
What interventions are being tested in trial NCT07321106?
The interventions under investigation include: CBI-1214 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07321106?
This trial is sponsored by Cartography Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07321106 being conducted?
This trial has 4 study locations across California, Michigan, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.